Aktienanalyse zu Amgen Inc (AMGN)AMGNAmgen Inc

Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Amgen is a good buy right now due to its current price of $414.87, which is below the analyst price target range of $430 to $470, suggesting potential upside. Additionally, the forward P/E ratio of 16.67 indicates that the stock is relatively undervalued compared to its earnings potential. However, investors should be cautious of the significant pricing pressures from government programs and competition from biosimilars, which pose a risk to future margins and growth.

25 analysts cover AMGN: 10 rate it Buy, 15 Hold and 0 Sell. The average price target is 363.10.